Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181826 · ClinicalTrials.gov registry record
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
A clinical trial, sponsored by Helio Genomics.
- Recruiting
- Registry status
- 1,200
- Enrollment target
NCT05181826: Recruiting study, sponsored by Helio Genomics.
NCT05181826 is a clinical trial that is actively recruiting participants, run by Helio Genomics. The registered enrollment target is 1,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05181826 is actively recruiting participants, sponsored by Helio Genomics.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
Study Summary
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Primary Outcome
The primary objective is to measure the performance (sensitivity and specificity) the multi-analyte blood Test for the detection of liver cancers in healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease.
Interventions
- DIAGNOSTIC_TEST Multi-analyte Blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2028-01 |
What NCT05181826 shows while recruiting
NCT05181826 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Multi-analyte Blood Test is the first listed.
NCT05181826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05181826 about?
NCT05181826 is a clinical study titled "Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer". To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) ...
What is the current status of trial NCT05181826?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2019-05-21. Estimated completion is 2028-01.
What interventions are being tested in trial NCT05181826?
The interventions under investigation include: Multi-analyte Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05181826?
This trial is sponsored by Helio Genomics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI